Estimates of the rate of growth of lymph nodes measured volumetrically predicts survival in cutaneous T-cell lymphoma (CTCL)

Autor: LM Fahmy, HR Yang, M Zhou, V Beylergil, CM Schreidah, LH Schwartz, T Fojo, SE Bates, LJ Geskin

Publikováno v: European Journal of Cancer. 173:S36

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bc2ce9edb8f4505fbf532ed76c3a0320
https://doi.org/10.1016/s0959-8049(22)00625-6

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel

Autor: Mh, Kang, Wd, Figg, Yukio Ando, Mv, Blagosklonny, Liewehr D, Fojo T, Se, Bates

Publikováno v: Europe PubMed Central

Overexpression of P-glycoprotein (Pgp) is one mechanism of drug resistance in cancer chemotherapy. A Phase I trial was conducted using PSC 833, a Pgp antagonist, in combination with paclitaxel in patients with refractory cancer. The objective of this

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::27bf655bdec12556c8b1bcae8d4522ac
https://pubmed.ncbi.nlm.nih.gov/11410497

Bryostatin 1 affects P-glycoprotein phosphorylation but not function in multidrug-resistant human breast cancer cells

Autor: Stefania Scala, Dickstein B, Regis J, Szallasi Z, Pm, Blumberg, Se, Bates

Publikováno v: Europe PubMed Central

The function of P-glycoprotein (Pgp), which confers multidrug resistance by active efflux of drug, is thought to be dependent on phosphorylation. Previous studies have suggested that protein kinase C (PKC) plays an important role in Pgp phosphorylati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::34d6e5248ec6995f04a2c83cedd49fe6
http://europepmc.org/abstract/med/9815959

Normal p53 status and function despite the development of drug resistance in human breast cancer cells

Autor: Wosikowski K, Jt, Regis, Rw, Robey, Alvarez M, Jeroen Buters, Jm, Gudas, Se, Bates

Publikováno v: Europe PubMed Central

Loss of or mutations in p53 protein have been shown to decrease both radio- and chemosensitivity. The present study assessed the p53 gene status, ability to arrest in G1 of the cell cycle, the functionality of the p53 transduction pathway, and apopto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::c2f631ffee206985a2f4fdac6b8adfc0
http://europepmc.org/abstract/med/8562478

Best Practices for Delivering Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.

Autor: Cloyd JM; Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus., Sarna A; Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus., Arango MJ; The Ohio State University Wexner Medical Center, Columbus., Bates SE; Columbia University Irving Medical Center, New York, New York., Bhutani MS; The University of Texas MD Anderson Cancer Center, Houston., Bloomston M; South Florida Surgical Oncology, Fort Myers., Chung V; City of Hope, Duarte, California., Dotan E; Fox Chase Cancer Center, Philadelphia, Pennsylvania., Ferrone CR; Cedars-Sinai, Los Angeles, California., Gambino PF; Abramson Cancer Center, University of Pennsylvania, Philadelphia., Goenka AH; Mayo Clinic, Rochester, Minnesota., Goodman KA; Icahn School of Medicine at Mount Sinai, New York, New York., Hall WA; Medical College of Wisconsin, Milwaukee., He J; Johns Hopkins University School of Medicine, Baltimore, Maryland., Hogg ME; NorthShore University HealthSystem, Chicago, Illinois., Jayaraman S; St Joseph's Health Centre Toronto, University of Toronto, Toronto, Ontario, Canada., Kambadakone A; Massachusetts General Hospital, Boston., Katz MHG; The University of Texas MD Anderson Cancer Center, Houston., Khorana AA; Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio., Ko AH; University of California San Francisco., Koay EJ; The University of Texas MD Anderson Cancer Center, Houston., Kooby DA; Emory University, Atlanta, Georgia., Krishna SG; The Ohio State University Wexner Medical Center, Columbus., Larsson LK; The University of Texas MD Anderson Cancer Center, Houston., Lee RT; City of Hope, Orange County, California., Maitra A; The University of Texas MD Anderson Cancer Center, Houston., Massarweh NN; Joseph M Cleland Atlanta VA Health Care System, Decature, Georgia., Mikhail S; Zangmeister Center, American Oncology Network, Columbus, Ohio., Muzaffar M; East Carolina University, Greenville, North Carolina., O'Reilly EM; Memorial Sloan Kettering Cancer Center, New York, New York., Palta M; Duke University, Durham, North Carolina., Petzel MQB; The University of Texas MD Anderson Cancer Center, Houston., Philip PA; Wayne State University, Henry Ford Health, Detroit, Michigan., Reyngold M; Memorial Sloan Kettering Cancer Center, New York, New York., Santa Mina D; St Joseph's Health Centre Toronto, University of Toronto, Toronto, Ontario, Canada., Sohal DPS; University of Cincinnati, Cincinnati, Ohio., Sundaresan TK; Kaiser Permanente, San Francisco, California., Tsai S; Division of Surgical Oncology, The Ohio State University Wexner Medical Center, Columbus., Turner KL; Moffitt Cancer Center, Tampa, Florida., Vreeland TJ; Brooke Army Medical Center, San Antonio, Texas., Walston S; The Ohio State University Wexner Medical Center, Wooster., Washington MK; Vanderbilt University Medical Center, Nashville, Tennessee., Williams TM; City of Hope, Duarte, California., Wo JY; Massachusetts General Hospital, Boston., Snyder RA; The University of Texas MD Anderson Cancer Center, Houston.

Publikováno v: JAMA surgery [JAMA Surg] 2024 Dec 04. Date of Electronic Publication: 2024 Dec 04.